© 2003 by Oxford University Press
Journal of the National Cancer Institute, Vol. 95, No. 7, 526-532,
April 2, 2003
© 2003 Oxford University Press
ARTICLE |
Estimates of the Number of U.S. Women Who Could Benefit From Tamoxifen for Breast Cancer Chemoprevention
Affiliations of authors: A. N. Freedman, R. Ballard-Barbash (Division of Cancer Control and Population Sciences), B. I. Graubard, S. R. Rao, M. H. Gail (Division of Cancer Epidemiology and Genetics), W. McCaskill-Stevens (Division of Cancer Prevention), National Cancer Institute, Bethesda, MD.
Correspondence to: Andrew N. Freedman, Ph.D., National Cancer Institute, EPN 4005 MSC 7344, 6130 Executive Blvd., Bethesda, MD 20892-7344 (e-mail: Andrew_Freedman{at}nih.gov).
Background: The Breast Cancer Prevention Trial demonstrated that tamoxifen treatment produced a 49% reduction in the risk of invasive breast cancer among women at elevated risk for the disease. The U.S. Food and Drug Administration (FDA) subsequently approved tamoxifen for women aged 35 years or older with a 5-year breast cancer risk of 1.67% or higher for breast cancer chemoprevention. However, tamoxifen use has been associated with adverse outcomes, and not all eligible women have a positive benefit/risk ratio. Methods: We used weighted data from the year 2000 National Health Interview Survey Cancer Control Module to estimate the total number of U.S. women, aged 35–79 years, who were eligible for tamoxifen chemoprevention based on the FDA eligibility criteria. We also estimated the numbers of white and black women who would benefit from tamoxifen chemoprevention on the basis of a positive benefit/risk index developed by Gail et al. Results: Of the 65 826 074 women aged 35–79 years without reported breast cancer in the United States in 2000, 10 232 816 women (15.5%, 95% confidence interval [CI] = 14.7% to 16.3%) would be eligible for tamoxifen chemoprevention. The percentage of U.S. women who would be eligible varied dramatically by race, with 18.7% (95% CI = 17.8% to 19.7%) of white women, 5.7% (95% CI = 4.3% to 7.5%) of black women, and 2.9% (95% CI = 2.1% to 3.9%) of Hispanic women being eligible. Of the 50 104 829 white U.S. women aged 35–79 years, 2 431 911 (4.9%, 95% CI = 4.3% to 5.4%) would have a positive benefit/risk index for tamoxifen chemoprevention. Of the 7 481 779 black U.S. women aged 35–79 years, only 42 768 (0.6%, 95% CI = 0.2% to 1.3%) would have a positive benefit/risk index. Among white women, 28 492 (95% CI = 24 693 to 32 292) breast cancers would be prevented or deferred if those women who have a positive net benefit index took tamoxifen over the next 5 years. Conclusion: A substantial percentage of U.S. women would be eligible for tamoxifen chemoprevention according to FDA criteria, but a much smaller percentage would have an estimated net benefit. Nevertheless, this latter percentage corresponds to more than two million women.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Brown Is tamoxifen a genotoxic carcinogen in women? Mutagenesis, September 1, 2009; 24(5): 391 - 404. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Ballard-Barbash, S. Hunsberger, M. H. Alciati, S. N. Blair, P. J. Goodwin, A. McTiernan, R. Wing, and A. Schatzkin Physical Activity, Weight Control, and Breast Cancer Risk and Survival: Clinical Trial Rationale and Design Considerations J Natl Cancer Inst, May 6, 2009; 101(9): 630 - 643. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Guerra, M. Sherman, and K. Armstrong Diffusion of Breast Cancer Risk Assessment in Primary Care J Am Board Fam Med, May 1, 2009; 22(3): 272 - 279. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Mahoney, T. Bevers, E. Linos, and W. C. Willett Opportunities and Strategies for Breast Cancer Prevention Through Risk Reduction CA Cancer J Clin, November 3, 2008; (2008) CA.2008.0016v1. [Abstract] [Full Text]
|
|
|
|
|
|
R. T. Chlebowski and N. Col Re: Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis J Natl Cancer Inst, September 17, 2008; 100(18): 1331 - 1332. [Full Text] [PDF]
|
|
|
|
|
|
M. H. Gail Discriminatory Accuracy From Single-Nucleotide Polymorphisms in Models to Predict Breast Cancer Risk J Natl Cancer Inst, July 16, 2008; 100(14): 1037 - 1041. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Tice, S. R. Cummings, R. Smith-Bindman, L. Ichikawa, W. E. Barlow, and K. Kerlikowske Using Clinical Factors and Mammographic Breast Density to Estimate Breast Cancer Risk: Development and Validation of a New Predictive Model Ann Intern Med, March 4, 2008; 148(5): 337 - 347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. Chlebowski, G. L. Anderson, D. S. Lane, A. K. Aragaki, T. Rohan, S. Yasmeen, G. Sarto, C. A. Rosenberg, F. A. Hubbell, and For the Women's Health Initiative Investigators Predicting Risk of Breast Cancer in Postmenopausal Women by Hormone Receptor Status J Natl Cancer Inst, November 21, 2007; 99(22): 1695 - 1705. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Fabian Tamoxifen or Raloxifene in Postmenopausal Women for Prevention of Breast Cancer: A Tale of Two Choices Counterpoint Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2210 - 2212. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Brown, E. M. Tompkins, D. J. Boocock, E. A. Martin, P. B. Farmer, K. W. Turteltaub, E. Ubick, D. Hemingway, E. Horner-Glister, and I. N.H. White Tamoxifen Forms DNA Adducts in Human Colon after Administration of a Single [14C]-Labeled Therapeutic Dose Cancer Res., July 15, 2007; 67(14): 6995 - 7002. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. L. Seewaldt, V. Goldenberg, L. W. Jones, C. Peace, G. Broadwater, V. Scott, G. R. Bean, L. G. Wilke, C. M. Zalles, and W. Demark-Wahnefried Overweight and Obese Perimenopausal and Postmenopausal Women Exhibit Increased Abnormal Mammary Epithelial Cytology Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 613 - 616. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Cuzick, J. F. Forbes, I. Sestak, S. Cawthorn, H. Hamed, K. Holli, and A. Howell Long-Term Results of Tamoxifen Prophylaxis for Breast Cancer--96-Month Follow-up of the Randomized IBIS-I Trial J Natl Cancer Inst, February 21, 2007; 99(4): 272 - 282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Armstrong, D. A. Quistberg, E. Micco, S. Domchek, and C. Guerra Prescription of tamoxifen for breast cancer prevention by primary care physicians. Arch Intern Med, November 13, 2006; 166(20): 2260 - 2265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. E. Barlow, E. White, R. Ballard-Barbash, P. M. Vacek, L. Titus-Ernstoff, P. A. Carney, J. A. Tice, D. S. M. Buist, B. M. Geller, R. Rosenberg, et al. Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst, September 6, 2006; 98(17): 1204 - 1214. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. G. Vogel and E. Taioli Have We Found the Ultimate Risk Factor for Breast Cancer? J. Clin. Oncol., April 20, 2006; 24(12): 1791 - 1794. [Full Text] [PDF]
|
|
|
|
 |
|
 P. R. Hutson, R. R. Love, T. C. Havighurst, E. Rogers, and J. F. Cleary Effect of Exemestane on Tamoxifen Pharmacokinetics in Postmenopausal Women Treated for Breast Cancer Clin. Cancer Res., December 15, 2005; 11(24): 8722 - 8727. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Parikh, N. Gildener-Leapman, A. Narendran, H.-Y. Lin, N. Lemanski, J. A. Bennett, H. I. Jacobson, and T. T. Andersen Prevention of N-Methyl-N-Nitrosourea-Induced Breast Cancer by {alpha}-Fetoprotein (AFP)-Derived Peptide, a Peptide Derived from the Active Site of AFP Clin. Cancer Res., December 1, 2005; 11(23): 8512 - 8520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Fisher, J. P. Costantino, D. L. Wickerham, R. S. Cecchini, W. M. Cronin, A. Robidoux, T. B. Bevers, M. T. Kavanah, J. N. Atkins, R. G. Margolese, et al. Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst, November 16, 2005; 97(22): 1652 - 1662. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C J Fabian, B F Kimler, M S Mayo, and S A Khan Breast-tissue sampling for risk assessment and prevention Endocr. Relat. Cancer, June 1, 2005; 12(2): 185 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. N. Freedman, D. Seminara, M. H. Gail, P. Hartge, G. A. Colditz, R. Ballard-Barbash, and R. M. Pfeiffer Cancer Risk Prediction Models: A Workshop on Development, Evaluation, and Application J Natl Cancer Inst, May 18, 2005; 97(10): 715 - 723. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Taylor and K. Taguchi Tamoxifen For Breast Cancer Chemoprevention: Low Uptake by High-Risk Women After Evaluation of a Breast Lump Ann. Fam. Med, May 1, 2005; 3(3): 242 - 247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Fabian and B. F. Kimler Selective Estrogen-Receptor Modulators for Primary Prevention of Breast Cancer J. Clin. Oncol., March 10, 2005; 23(8): 1644 - 1655. [Full Text] [PDF]
|
|
|
|
|
|
B. K. Dunn, D. L. Wickerham, and L. G. Ford Prevention of Hormone-Related Cancers: Breast Cancer J. Clin. Oncol., January 10, 2005; 23(2): 357 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Newman Breast Cancer in African-American Women Oncologist, January 1, 2005; 10(1): 1 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Ozanne and L. J. Esserman Evaluation of Breast Cancer Risk Assessment Techniques: A Cost-effectiveness Analysis Cancer Epidemiol. Biomarkers Prev., December 1, 2004; 13(12): 2043 - 2052. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Lewis, L. S. Kinsinger, R. P. Harris, and R. J. Schwartz Breast Cancer Risk in Primary Care: Implications for Chemoprevention Arch Intern Med, September 27, 2004; 164(17): 1897 - 1903. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. R. Yabroff, N. Breen, S. W. Vernon, H. I. Meissner, A. N. Freedman, and R. Ballard-Barbash What Factors Are Associated with Diagnostic Follow-Up after Abnormal Mammograms? Findings from a U.S. National Survey Cancer Epidemiol. Biomarkers Prev., May 1, 2004; 13(5): 723 - 732. [Abstract] [Full Text] [PDF]
|
|